Cognitive impairment in patients with Aids – Prevalence and severity

HIV/AIDS - Research and Palliative Care

Volumn 7, Issue , 2015, Pages 35-47

  Watkins, Crystal C ^a   Treisman, Glenn J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Delirium; Dementia; Depression; HAND; HIV; HIV associated neurocognitive disorder

Indexed keywords

ANTIRETROVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; CORTICOSTEROID; DEXAMPHETAMINE; EFAVIRENZ; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; INTERFERON; LORAZEPAM; MEMANTINE; METHYLPHENIDATE; MOLINDONE; NEUROLEPTIC AGENT; NIMODIPINE; OLANZAPINE; PAROXETINE; PEMOLINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFONAMIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAMNESIS; ARTICLE; ASTROCYTE; CATATONIA; CENTRAL NERVOUS SYSTEM INFECTION; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSTHYMIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GROUP THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; LIFE EXPECTANCY; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; META ANALYSIS (TOPIC); MICROGLIA; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT HEALTH QUESTIONNAIRE 2; PATIENT HEALTH QUESTIONNAIRE 9; PREVALENCE; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; SUBCORTEX; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

EID: 84922242108     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S39665     Document Type: Article

References (133)

1. UNAIDS. 2013 UNAIDS Report on the Global AIDS Epidemic; 2013. Available form: http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2013/g r2013/ UNAIDS_Global_Report_2013_en.pdf. Accessed May 27, 2013.
2. Center for Disease Control (CDC). HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas. Atlanta, GA: US Department of Health and Human Services, CDC; 2005 [online]. Atlanta, GA: US Department of Health and Human Services, CDC; 2011.
3. Simone MJ, Appelbaum J. HIV in older adults. Geriatrics. 2008;63(12):6–12.
4. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging. 2008;3(3):453–472.
5. Zablotsky D, Kennedy M. Risk factors and HIV transmission to midlife and older women: knowledge, options, and the initiation of safer sexual practices. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S122–S130.
6. Butt AM, Nandwani R. Sexually transmitted diseases in HIV-1-infected patients. Lancet. 2001;357(9267):1533.
7. McArthur JC, Sacktor N, Selnes O. Human immunodefciency virus-associated dementia. Semin Neurol. 1999;19(2):129–150.
8. Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neu-rocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004; 18(Suppl 1):S49–S59.
9. Goodkin K, Wilkie FL, Concha M, et al. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol. 2001;54(Suppl 1):S35–S43.
10. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63(5):822–827.
11. Janssen RS, St Louis ME, Satten GA, et al. HIV infection among patients in US acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group. N Engl J Med. 1992;327(7):445–452.
12. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
13. HRSA. HIV-Associated Dementia and Other Neurocognitive Disorders. Guide for HIV/AIDS Clinical Care, 2014. Available from: http:// hab.hrsa.gov/deliverhivaidscare/2014guide.pdf. Accessed October 27, 2014.
14. Cross S, Onen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol. 2013;8(5):1114–1122.
15. Havlik RJ, Brennan M, Karpiak SE. Comorbidities and depression in older adults with HIV. Sex Health. 2011;8(4):551–559.
16. Sonneville R, Ferrand H, Tubach F, et al. Neurological complications of HIV infection in critically ill patients: clinical features and outcomes. J Infect. 2011;62(4):301–308.
17. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med. 1995;25(1):53–67.
18. Inouye SK. Delirium in hospitalized older patients: recognition and risk factors. J Geriatr Psychiatry Neurol. 1998;11(Fall 3):118–125; discussion 157–158.
19. Perry S, Marotta R F. AIDS dementia: a review of the literature. Alzheimer Dis Assoc Disord. 1987;1(4):221–235.
20. Angelino AF, Treisman GJ. Issues in co-morbid severe mental illnesses in HIV infected individuals. Int Rev Psychiatry. 2008;20(1):95–101.
21. Uldall KK, Berghuis J P. Delirium in AIDS patients: recognition and medication factors. AIDS Patient Care STDS. 1997;11(6):435–441.
22. Uldall KK, Harris VL, Lalonde B. Outcomes associated with delirium in acutely hospitalized acquired immune defciency syndrome patients. Compr Psychiatry. 2000;41(2):88–91.
23. Uldall KK, Ryan R, Berghuis J P, Harris VL. Association between delirium and death in AIDS patients. AIDS Patient Care STDS. 2000;14(2):95–100.
24. Hatherill S, Flisher A. Delirium in children with HIV/AIDS. J Child Neurol. 2009;24(7):879–883.
25. Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother. 2013;47(1):75–89.
26. Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug therapy for delirium in terminally ill adult patients. Cochrane Database Syst Rev. 2012;11:CD004770.
27. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153(2):231–237.
28. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodefciency virus disease. Arch Intern Med. 2001;161(3):411–420.
29. Seitz D P, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007;68(1):11–21.
30. Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol. 2008;14(5):362–367.
31. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother. 2002;36(5):827–830.
32. Dolder CR, Patterson TL, Jeste D V. HIV, psychosis and aging: past, present and future. AIDS. 2004;18(Suppl 1):S35–S42.
33. Fernandez F, Levy JK, Mansell P W. Management of delirium in terminally ill AIDS patients. Int J Psychiatry Med. 1989;19(2):165–172.
34. Itoh K, Mehraein P, Weis S. Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol. 2000;99(4):376–384.
35. Ferrando SJ, Wapenyi K. Psychopharmacological treatment of patients with HIV and AIDS. Psychiatr Q. 2002;73(Spring 1):33–49.
36. Carrico AW, Johnson MO, Morin S F, et al. Correlates of suicidal ideation among HIV-positive persons. AIDS. 2007;21(9):1199–1203.
37. Leso L, Schwartz TL. Ziprasidone treatment of delirium. Psychosomatics. 2002;43(1):61–62.
38. Cysique LA, Deutsch R, Atkinson JH, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc. 2007;13(1):1–11.
39. Gibbie T, Hay M, Hutchison C W, Mijch A. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health. 2007;4(4):227–232.
40. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–730.
41. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. JAMA. 1993;270(21):2563–2567.
42. Watkins CC, Treisman GJ. Neuropsychiatric complications of aging with HIV. J Neurovirol. 2012;18(4):277–290.
43. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fuoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004;24(4):379–385.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition – Text Revision (DSMIV-TR). Washington, DC: American Psychiatric Association; 2000.
45. Watkins CC, Pieper AA, Treisman GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf. 2011;34(8):623–639.
46. Nakimuli-Mpungu E, Musisi S, Katabira E, Nachega J, Bass J. Prevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern Uganda. J Affect Disord. 2011;135(1–3):160–167.
47. Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS. 2005;19(11):728–736.
48. Tsai AC, Mimiaga MJ, Dilley J W, et al. Does effective depression treatment alone reduce secondary HIV transmission risk? Equivocal fndings from a randomized controlled trial. AIDS Behav. 2013;17(8):2765–2772.
49. Treisman GJ, Angelino A F, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. 2001;286(22):2857–2864.
50. Himelhoch S, Brown CH, Walkup J, et al. HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009;23(13):1735–1742.
51. Alciati A, Gallo L, Monforte AD, Brambilla F, Mellado C. Major depression-related immunological changes and combination anti-retroviral therapy in HIV-seropositive patients. Hum Psychopharmacol. 2007;22(1):33–40.
52. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11):1466–1474.
53. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry. 1996;153(11):1430–1437.
54. Sherr L, Harding R, Lampe F, et al. Clinical and behavioural aspects of aging with HIV infection. Psychol Health Med. 2009;14(3):273–279.
55. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/ beta-catenin signaling. Cell. 2009;136(6):1017–1031.
56. Hirshfeld S, Wolitski RJ, Chiasson MA, Remien RH, Humberstone M, Wong T. Screening for depressive symptoms in an online sample of men who have sex with men. AIDS Care. 2008;20(8):904–910.
57. Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med. 1994;24(2):103–113.
58. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neurop-sychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714–721.
59. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42(12):1790–1799.
60. Clifford DB, Evans S, Yang Y, Acosta E P, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10(6):343–355.
61. Ferrando SJ, Freyberg Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry. 2008;20(1):61–71.
62. Akena D, Stein DJ, Joska J. Does screening HIV-positive individuals in Uganda for major depressive disorder improve case detection rates and antidepressant prescription? AIDS Behav. 2012;17(8):2802–2807.
63. Huang TL, Leu HS, Liu J W. Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study. Psychiatry Clin Neurosci. 2006;60(6):687–692.
64. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, infammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625–633.
65. Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151(4):516–523.
66. Rabkin JG, Rabkin R, Wagner G. Effects of fuoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55(3):92–97.
67. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156(1):101–107.
68. Tsai AC, Karasic DH, Hammer G P, et al. Directly observed antidepres-sant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2012;103(2):308–315.
69. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 1998;59(5):217–224.
70. Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010;67(12):1282–1290.
71. Kumar V, Encinosa W. Effects of antidepressant treatment on antiret-roviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80(3):131–141.
72. Schroecksnadel K, Sarcletti M, Winkler C, et al. Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun. 2008;22(6):881–889.
73. Sevigny JJ, Albert SM, McDermott M P, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurolog y. 2004;63(11):2084–2090.
74. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239(4840):586–592.
75. Koutsilieri E, Sopper S, Scheller C, Ter Meulen V, Riederer P. Parkinsonism in HIV dementia. J Neural Transm. 2002;109(5–6):767–775.
76. Koutsilieri E, Sopper S, Scheller C, Ter Meulen V, Riederer P. Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm. 2002;109(3):399–410.
77. Mirsattari SM, Power C, Nath A. Parkinsonism with HIV infection. Mov Disord. 1998;13(4):684–689.
78. Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry. 1991;148(11):1558–1561.
79. Dunlop O, Bjørklund R, Bruun JN, et al. Early psychomotor slowing predicts the development of HIV dementia and autopsy-verifed HIV encephalitis. Acta Neurol Scand. 2002;105(4):270–275.
80. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2007;18(2):45–55.
81. Levine AJ, Hinkin CH, Ando K, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol. 2008;30(7):836–843.
82. Koski L, Brouillette MJ, Lalonde R, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment (*). HIV Med. 2011;12(8):472–480.
83. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61(6):436–440.
84. Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodefciency virus infection. Arch Neurol. 1987;44(1):65–69.
85. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–2252.
86. Sacktor N, McDermott M P, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8(2):136–142.
87. Sacktor N. The epidemiology of human immunodefciency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(Suppl 2):115–121.
88. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodefciency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–221.
89. Stern Y, McDermott M P, Albert S, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol. 2001;58(3):473–479.
90. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodefciency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11(3):265–273.
91. Bolokadze N, Gabunia P, Ezugbaia M, Gatserelia L, Khechiashvili G. Neurological complications in patients with HIV/AIDS. Georgian Med News. 2008;(165):34–38.
92. Wojna V, Skolasky RL, Hechavarría R, et al. Prevalence of human immunodefciency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. 2006;12(5):356–364.
93. Jowi JO, Mativo PM, Musoke SS. Clinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/AIDS at the Nairobi hospital. East Afr Med J. 2007;84(2):67–76.
94. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neu-rocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurolog y. 2010;75(23):2087–2096.
95. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodefciency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol. 2010;67(6):699–714.
96. Finzi D, Hermankova M, Pierson T, et al. Identifcation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–1300.
97. Anthony IC, Ramage SN, Carnie F W, Simmonds P, Bell JE. Infuence of HAART on HIV-related CNS disease and neuroinfammation. J Neuropathol Exp Neurol. 2005;64(6):529–536.
98. Anthony IC, Ramage SN, Carnie F W, Simmonds P, Bell JE. Does drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection? Neuropathol Appl Neurobiol. 2005;31(3):325–338.
99. Cysique LA, Brew BJ. Neuropsychological functioning and anti-retroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009;19(2):169–185.
100. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69–81.
101. Kaul M. HIV’s double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci. 2008;13:2484–2494.
102. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocogni-tive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010;17(1):3–16.
103. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13(10):1249–1253.
104. Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10(4):246–252.
105. Hasbun R, Eraso J, Ramireddy S, et al. Screening for neurocognitive impairment in HIV individuals: the utility of the Montreal Cognitive Assessment Test. J AIDS Clin Res. 2013;3(10):186.
106. Gandhi NS, Moxley RT, Creighton J, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. 2010;4(3):371–379.
107. Davis HF, Skolasky RL Jr, Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modifed HIV dementia scale versus the Grooved Pegboard. AIDS Read. 2002;12(1):29–31, 38.
108. Oshinaike OO, Akinbami AA, Ojo OO, Ojini I F, Okubadejo UN, Danesi AM. Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy. AIDS Res Treat. 2012;2012:581531.
109. Descamps M, Hyare H, Zerizer I, J A Ger H. Neuroimaging of CNS involvement in HIV. J HIV Ther. 2008;13(3):48–54.
110. Roc AC, Ances BM, Chawla S, et al. Detection of human immunode-fciency virus induced infammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol. 2007;64(9):1249–1257.
111. Thurnher MM, Schindler EG, Thurnher SA, Pernerstorfer-Schon H, Kleibl-Popov C, Rieger A. Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging fndings and clinical course. AJNR Am J Neuroradiol. 2000;21(4):670–678.
112. Descamps M, Hyare H, Stebbing J, Winston A. Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J HIV Ther. 2008;13(3):55–58.
113. Sundgren PC, Dong Q, Gomez-Hassan D, Mukherji SK, Maly P, Welsh R. Diffusion tensor imaging of the brain: review of clinical applications. Neuroradiolog y. 2004;46(5):339–350.
114. Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage. 2004;23(4):1336–1347.
115. Mohamed MA, Barker PB, Skolasky RL, et al. Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging. 2010;28(9):1251–1257.
116. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage. 2004;23(3):928–935.
117. Meyerhoff DJ, MacKay S, Bachman L, et al. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodefciency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology. 1993; 43(3 pt 1):509–515.
118. Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002;59(9):1343–1349.
119. Schiftto G, Kieburtz K, McDermott M P, et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology. 2001;56(3):415–418.
120. Uthman OA, Abdulmalik JO. Adjunctive therapies for AIDS dementia complex. Cochrane Database Syst Rev. 2008;(3):CD006496.
121. Robinson-Papp J, Elliott KJ, Simpson DM. HIV-related neu-rocognitive impairment in the HAART era. Curr HIV/AIDS Rep. 2009;6(3):146–152.
122. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21(8):706–713.
123. Winston A, Puls R, Kerr SJ, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med. 2011;13(4):245–251.
124. Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol. 1999;21(6):737–756.
125. Heseltine PN, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55(1):41–51.
126. Consortium D. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodefciency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology. 1998;50(3):645–651.
127. Schiftto G, Navia BA, Yiannoutsos CT, et al; Adult AIDS Clinical Trial Group (ACTG) 301, 700 Teams, HIV MRS Consortium. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877–1886.
128. Kieburtz KD, Giang DW, Schiffer RB, Vakil N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction. Arch Neurol. 1991;48(3):312–314.
129. Mintz M, Tardieu M, Hoyt L, McSherry G, Mendelson J, Oleske J. Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes. Neurology. 1996;47(6): 1583–1585.
130. Hinkin CH, Castellon SA, Hardy DJ, Farinpour R, Newton T, Singer E. Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci. 2001;13(Spring 2):248–254.
131. Czub S, Koutsilieri E, Sopper S, et al. Enhancement of central nervous system pathology in early simian immunodefciency virus infection by dopaminergic drugs. Acta Neuropathol. 2001;101(2): 85–91.
132. Dettling M, Muller-Oerlinghausen B, Britsch P. Clozapine treatment of HIV-associated psychosis – too much bone marrow toxicity? Pharmacopsychiatry. 1998;31(4):156–157.
133. Zilikis N, Nimatoudis I, Kiosses V, Ierodiakonou C. Treatment with risperidone of an acute psychotic episode in a patient with AIDS. Gen Hosp Psychiatry. 1998;20(6):384–385.